NCT00448760View on ClinicalTrials.gov

Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Esophageal Cancer
Interventions
DRUG

Docetaxel

Intravenously, 25 mg/m2, over 30 minutes, 2 cycles

DRUG

Floxuridine

Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles

DRUG

Leucovorin

Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles

DRUG

Oxaliplatin

Intravenously, 85 mg/m2, over 2 hours, 2 cycles

GENETIC

Microarray analysis

Analysis of tumor for pathologic response to protocol therapy

GENETIC

reverse transcriptase-polymerase chain reaction

Analysis of tumor for pathologic response to protocol therapy

PROCEDURE

Conventional surgery

Surgical removal of tumor for correlative studies

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT00448760 - Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery | Biotech Hunter | Biotech Hunter